Food for thought...a gourmet meal I have only b
Post# of 148186
(Total Views: 763)
Posted On: 09/04/2021 2:22:12 AM
Food for thought...a gourmet meal
I have only been with this stock since the beginning of the pandemic, so I missed a lot of the "in the past" stuff. Gradually, I'm picking up bits and pieces of the information, but it's difficult to discern truth from BS and hyperbole.
Based on my observations, since getting involved, I think Nader has really tried to get Leronlimab approved. But this operation needs more than a "one-man-band." He had to "farm things out" to get the expertise necessary. Unfortunately, some of the "contractors" chosen were probably based on "getting things done on the cheap" over getting things DONE RIGHT THE FIRST TIME! That's when things got pretty "hinky."
Example: Getting Bruce Patterson involved seemed to be a good idea, based on his knowledge base/background in immunology and analytics, but only after the fact do we find out about the shenanigans that unfolded based on that decision.
Also who was responsible for the trial designs? Was this a Nader D-I-Y and/or who else was involved? Whoever was on the planning end of things got a lot of stuff right, but not enough to get leronlimab over the goal line. There were some glaring errors - that became apparent after-the-fact. Anticipating all of the potential problems is an extreme challenge and I don't think that's unique to just CytoDyn. Still, doing things "on the cheap" (which was probably a necessity) turned out to be expensive in retrospect.
I think Nader has tried to be creative in advancing Leronlimab, but he's working against a "stacked deck." Leronlimab is revolutionary - probably beyond what most people even here realize.* Yes, it obviously is a concern to other BioPharmaceutical firms because of its safety and its numerous applications. These pose a serious threat to the various "pipelines" current and future of the different companies. For that reason they're adamantly opposed to any sort of approval that allows CytoDyn/leronlimab to get traction. You can expect them to INSIST that the FDA and regulatory agencies do everything possible to impede Leronlimab's approval or being granted an EUA. CytoDyn is being held to the standard of perfection as opposed to members of the BP fraternity.
This is to be expected, since BP pays almost 45% of the FDA's expenses and key members of the FDA do not have (at the highest level of expertise) too many employers to choose from other than Government, Academia, or (for the really spiffy salaries) BP. So decision makers may also be considering their own future (read employment/remuneration) when they make their decisions.
CytoDyn is also being bashed by other "factors" that may be entirely coincidental or maybe not. As mentioned before - Waves of short transactions that the SEC seems to turn a blind eye to, False articles, full-time board/internet bashers, even some help in getting foreign governments to shun Cytodyn. This may, at first glance, appear unbelievable, but BP throws its money around quite generously maintaining its hegemony.
https://www.opensecrets.org/industries/summar...&mem=Y
A call to key congress people (who will not bite the hand that feeds their re-election funding) and a country may reconsider its position when it comes to receiving crucial foreign aid.
Example: About the time CytoDyn was trying to get approval of Leronlimab in the Philippines, the Philippines was faced with serious Chinese incursions into its off-shore waters by the Chinese fishing fleet. Protecting those waters and trying to avoid the Chinese getting a foothold was certainly more important than approving Leronlimab. Do I know this for a fact....no, but "hot on leronlimab went to stone cold quiet" as the US gave the Philippines reasurances of its support. Hmmmm.
It's not easy to get Leronlimab approved and it's far beyond Nader's fault that it hasn't happened.
As to his enrichment. Without Nader Pourhassan Ph. D. we wouldn't be having this discussion. It's because of him, positive and negative, that we are at this point. I don't know how much of the banter about his "excessive pay" is true, but I don't know that his "pay" is especially excessive. Have you looked at what other CEO's are making and the BS they pull. I insist on voting all of my numerous proxies and I rarely approve the incentives, options and pay raises that the other Boards/CEOs/Committees ask for. Most are, in my estimation, overpaid at my expense. At least Nader is "DOING SOMETHING FOR THE MONEY AND TRIES TO KEEP ME (AND YOU) INFORMED!"
That's a welcome change compared to most of the stocks/companies that I own infinitesimal pieces of. LOL
Finally, I mentioned something in a few posts and I'm not sure many picked up on the significance. When you contract Covid-19 and get injections of Leronlimab - yes - it does "its thing" in dealing with the immunological imbalances and reorientations.
But
*That same leronlimab is not just addressing the Covid. It is active throughout the body and is simultaneously addressing immunological imbalances/inflammation elsewhere. If you follow some of the latest pronouncements re: health - inflammation, while having its uses, can be a major cause of problems - especially chronic inflammation. It appears that inflammation has the potential to greatly aggravate situations even those of a neurodegenerative nature.
To support this conjecture - I suggest your re-visit the anomaly that appeared in the results generated by the CD10 trial.
"The incidence, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs) were lower in the leronlimab group compared to the placebo group. Patients treated with placebo were more than twice as likely to experience SAEs or AEs compared to patients treated with leronlimab."
(https://www.cytodyn.com/newsroom/press-releases/detail/458/cytodyn-announces-clinically-significant-top-line-results)
This is a totally unexpected result!! But it lends support to my conjecture and >>>
This suggests that leronlimab might be considered one of the substances showing potential to play a role in life extension or perhaps more importantly "Quality of Life" extension.
Leronlimab is truly the golden fleece -
AT ALL COSTS -
WE MUST NOT LOSE IT!
IMO
I have only been with this stock since the beginning of the pandemic, so I missed a lot of the "in the past" stuff. Gradually, I'm picking up bits and pieces of the information, but it's difficult to discern truth from BS and hyperbole.
Based on my observations, since getting involved, I think Nader has really tried to get Leronlimab approved. But this operation needs more than a "one-man-band." He had to "farm things out" to get the expertise necessary. Unfortunately, some of the "contractors" chosen were probably based on "getting things done on the cheap" over getting things DONE RIGHT THE FIRST TIME! That's when things got pretty "hinky."
Example: Getting Bruce Patterson involved seemed to be a good idea, based on his knowledge base/background in immunology and analytics, but only after the fact do we find out about the shenanigans that unfolded based on that decision.
Also who was responsible for the trial designs? Was this a Nader D-I-Y and/or who else was involved? Whoever was on the planning end of things got a lot of stuff right, but not enough to get leronlimab over the goal line. There were some glaring errors - that became apparent after-the-fact. Anticipating all of the potential problems is an extreme challenge and I don't think that's unique to just CytoDyn. Still, doing things "on the cheap" (which was probably a necessity) turned out to be expensive in retrospect.
I think Nader has tried to be creative in advancing Leronlimab, but he's working against a "stacked deck." Leronlimab is revolutionary - probably beyond what most people even here realize.* Yes, it obviously is a concern to other BioPharmaceutical firms because of its safety and its numerous applications. These pose a serious threat to the various "pipelines" current and future of the different companies. For that reason they're adamantly opposed to any sort of approval that allows CytoDyn/leronlimab to get traction. You can expect them to INSIST that the FDA and regulatory agencies do everything possible to impede Leronlimab's approval or being granted an EUA. CytoDyn is being held to the standard of perfection as opposed to members of the BP fraternity.
This is to be expected, since BP pays almost 45% of the FDA's expenses and key members of the FDA do not have (at the highest level of expertise) too many employers to choose from other than Government, Academia, or (for the really spiffy salaries) BP. So decision makers may also be considering their own future (read employment/remuneration) when they make their decisions.
CytoDyn is also being bashed by other "factors" that may be entirely coincidental or maybe not. As mentioned before - Waves of short transactions that the SEC seems to turn a blind eye to, False articles, full-time board/internet bashers, even some help in getting foreign governments to shun Cytodyn. This may, at first glance, appear unbelievable, but BP throws its money around quite generously maintaining its hegemony.
https://www.opensecrets.org/industries/summar...&mem=Y
A call to key congress people (who will not bite the hand that feeds their re-election funding) and a country may reconsider its position when it comes to receiving crucial foreign aid.
Example: About the time CytoDyn was trying to get approval of Leronlimab in the Philippines, the Philippines was faced with serious Chinese incursions into its off-shore waters by the Chinese fishing fleet. Protecting those waters and trying to avoid the Chinese getting a foothold was certainly more important than approving Leronlimab. Do I know this for a fact....no, but "hot on leronlimab went to stone cold quiet" as the US gave the Philippines reasurances of its support. Hmmmm.
It's not easy to get Leronlimab approved and it's far beyond Nader's fault that it hasn't happened.
As to his enrichment. Without Nader Pourhassan Ph. D. we wouldn't be having this discussion. It's because of him, positive and negative, that we are at this point. I don't know how much of the banter about his "excessive pay" is true, but I don't know that his "pay" is especially excessive. Have you looked at what other CEO's are making and the BS they pull. I insist on voting all of my numerous proxies and I rarely approve the incentives, options and pay raises that the other Boards/CEOs/Committees ask for. Most are, in my estimation, overpaid at my expense. At least Nader is "DOING SOMETHING FOR THE MONEY AND TRIES TO KEEP ME (AND YOU) INFORMED!"
That's a welcome change compared to most of the stocks/companies that I own infinitesimal pieces of. LOL
Finally, I mentioned something in a few posts and I'm not sure many picked up on the significance. When you contract Covid-19 and get injections of Leronlimab - yes - it does "its thing" in dealing with the immunological imbalances and reorientations.
But
*That same leronlimab is not just addressing the Covid. It is active throughout the body and is simultaneously addressing immunological imbalances/inflammation elsewhere. If you follow some of the latest pronouncements re: health - inflammation, while having its uses, can be a major cause of problems - especially chronic inflammation. It appears that inflammation has the potential to greatly aggravate situations even those of a neurodegenerative nature.
To support this conjecture - I suggest your re-visit the anomaly that appeared in the results generated by the CD10 trial.
"The incidence, frequency, and severity of adverse events (AEs) and serious adverse events (SAEs) were lower in the leronlimab group compared to the placebo group. Patients treated with placebo were more than twice as likely to experience SAEs or AEs compared to patients treated with leronlimab."
(https://www.cytodyn.com/newsroom/press-releases/detail/458/cytodyn-announces-clinically-significant-top-line-results)
This is a totally unexpected result!! But it lends support to my conjecture and >>>
This suggests that leronlimab might be considered one of the substances showing potential to play a role in life extension or perhaps more importantly "Quality of Life" extension.
Leronlimab is truly the golden fleece -
AT ALL COSTS -
WE MUST NOT LOSE IT!
IMO
(20)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼